Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Cash from Financing Activities (2022 - 2025)

Bioregenx (BRGX) has 4 years of Cash from Financing Activities data on record, last reported at $70833.0 in Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 52.52% year-over-year to $70833.0; the TTM value through Sep 2025 reached $70297.0, down 92.7%, while the annual FY2024 figure was $442119.0, 63.29% down from the prior year.
  • Cash from Financing Activities reached $70833.0 in Q3 2025 per BRGX's latest filing, up from $16823.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $513370.0 in Q4 2023 and bottomed at -$10415.0 in Q1 2025.
  • Average Cash from Financing Activities over 4 years is $126046.6, with a median of $58637.5 recorded in 2024.
  • Peak YoY movement for Cash from Financing Activities: soared 14571.91% in 2023, then tumbled 103.69% in 2025.
  • A 4-year view of Cash from Financing Activities shows it stood at $3499.0 in 2022, then skyrocketed by 14571.91% to $513370.0 in 2023, then plummeted by 101.35% to -$6944.0 in 2024, then soared by 1120.06% to $70833.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $70833.0 in Q3 2025, $16823.0 in Q2 2025, and -$10415.0 in Q1 2025.